![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Ranbaxy Laboratories Limited Gurgaon In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Doxycycline monohydrate, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 1997-072 - Rev 03
This Chemical Type CEP, issued on March 17, 2008, remains in force until March 24, 2015, ensuring its reliability within the pharmaceutical industry.
Substance Number 820 associated with this CEP further emphasizes